Literature DB >> 3156909

A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness.

T R Norman, D Ames, G D Burrows, B Davies.   

Abstract

A double blind comparative study of amitriptyline and a new reversible MAO A inhibitor R011-1163 was conducted in 25 depressed inpatients over 4 weeks. Response to treatment was assessed with the Hamilton depression rating scale, the Carroll depression self rating scale and the Visual analogue scale. Both drugs produced significant changes in depressive symptomatology (P less than 0.01, MANOVA) and there were no statistically significant differences between drugs (P greater than 0.05 MANOVA). Side effects were of mild to moderate severity with dry mouth the most commonly reported side effect of amitriptyline and vague, generalised headache in patients, treated with R011-1163.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156909     DOI: 10.1016/0165-0327(85)90069-2

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  8 in total

1.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.

Authors:  M Koulu; M Scheinin; A Kaarttinen; J Kallio; K Pyykkö; J Vuorinen; R H Zimmer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  Monoamine oxidase inhibitors: clinical review.

Authors:  R A Remick; C Froese
Journal:  Can Fam Physician       Date:  1990-06       Impact factor: 3.275

3.  Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines.

Authors:  J Fritze; G Laux; E Sofic; P Koronakis; M P Schoerlin; P Riederer; H Beckmann
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.

Authors:  I Berlin; R Zimmer; H M Thiede; C Payan; T Hergueta; L Robin; A J Puech
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 5.  Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs.

Authors:  M V Rudorfer; W Z Potter
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Moclobemide excretion in human breast milk.

Authors:  G Pons; M P Schoerlin; Y K Tam; C Moran; J P Pfefen; C Francoual; A M Pedarriosse; J Chavinie; G Olive
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

7.  Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.

Authors:  C Audebert; O Blin; S Monjanel-Mouterde; P Auquier; A M Pedarriosse; J Dingemanse; A Durand; J P Cano
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.

Authors:  Ajit Avasthi; Parmanand Kulhara; Gagandeep Singh; Rajni Sharma; Rajinder P Kaur
Journal:  Indian J Psychiatry       Date:  2005-04       Impact factor: 1.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.